Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

31.76 +0.52 (+1.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 260,804
Open 30.97
Bid (Size) 31.39 (1)
Ask (Size) 32.11 (1)
Prev. Close 31.24
Today's Range 30.50 - 32.24
52wk Range 27.00 - 81.13
Shares Outstanding 53,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
Where Arvinas Stands With Analysts
 
Via Benzinga

Performance

YTD
-4.80%
-4.80%
1 Month
-7.73%
-7.73%
3 Month
-36.11%
-36.11%
6 Month
-36.96%
-36.96%
1 Year
-51.81%
-51.81%

More News

Read More
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Looking Into Arvinas's Return On Invested Capital
Via Benzinga
Analyst Ratings for Arvinas
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arvinas Inc.
Via Globe NewsWire
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via Globe NewsWire
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Via Benzinga
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Via Benzinga
Abercrombie & Fitch To Rally 21%? Plus This Analyst Predicts $237 For Autodesk
Via Benzinga
Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting
Via Benzinga
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
From Arvinas Inc.
Via Globe NewsWire
Carvana, Crocs And Other Big Losers From Monday
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Why TuanChe Shares Are Trading Lower By 76%? Here Are 48 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via Globe NewsWire
Arvinas to Present at Upcoming Conferences
From Arvinas Inc.
Via Globe NewsWire
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
From Arvinas Inc.
Via Globe NewsWire
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
From Arvinas Inc.
Via Globe NewsWire
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Arvinas Gives Back to Local Greater New Haven Community
From Arvinas Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.